ABSTRACT
Condition:
Hyposmia;Parkinson DiseaseIntervention:
Diagnostic Test: The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)Primary outcome:
The VSIT score of both groupsCriteria:
Inclusion Criteria:
- Aged 18 years and older
- MMSE score > 24
- Clinical diagnosis of Parkinson's disease (for patient group)
Exclusion Criteria:
- History of trauma to the head, history of nasal bone fracture, and history of nasal
cosmetic surgery
- Brain neoplasms
- History of stroke, epilepsy
- Secondary Parkinson's and Parkinson's Plus
- Other neurodegenerative diseases, such as Alzheimer's
- Mental disorders, such as schizophrenia, depression
- Upper respiratory tract infections in the 2 weeks
- Pregnancy
- Exposure to medications relating to olfactory reduction, for instance, some particular
antibiotics, antiepileptics, antithyroid or benzodiazepines
- Having reported COVID-19 compatible smell symptomatology
ABSTRACT
Responses from stock markets to the Covid-19 pandemic appear to change over time. Recent responses might differ as herd mentality in stock markets tends to become herd immunity to the pandemic. This study revisits the pandemic's effects on the Asia-Pacific countries' market volatility over the past 25 months. Primarily, we examine the changes of the impacts of the pandemic on volatility between the first pandemic period (2020) and the second period (January 2021-January 2022). Our findings indicate that implementing pandemic control measures helps reduce market volatility at the country and region levels. The effects of new Covid-19 cases and pandemic control measures on market volatility have been dramatically fading since 2021. The Toda-Yamamoto causality test and the panel impulse response functions from panel VAR estimation are also used for robustness analysis. Based on our findings, it appears that the current pandemic may no longer be blamed for stock market volatility in the Asia-Pacific region.
ABSTRACT
Condition:
COVID-19 Pandemic;Quality of LifeIntervention:
Drug: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)Primary outcome:
Quality of Life (QoL) questionnaireCriteria:
Inclusion Criteria:
- Patients able to understand and fill out a questionnaire
- From full 18 to 64 years old;
- Patients with the mild and moderate COVID-19 who used Shen Cao Gan Jiang Tang in the
acute phase for intervention group.
- Participants enrolled in protocol NCT05055427.
- Voluntarily consented to participate in the study
Exclusion Criteria:
- Patient who are not able to complete 100% of the questionnaire Criteria for stopping
the study
- The patient cannot be contacted after 04 calls, each call is at least 06 hours apart
on the survey days.
- The patient does not want to continue participating in the study.
ABSTRACT
Vietnam has been considered one of the few countries that put the COVID-19 pandemic under control and successfully achieved solid economic growth in 2020. However, the national economy has been hit hard by the pandemic in 2021. National borders across the countries have been closed for an extended time. As such, supporting local industries is essential to sustain economic growth. This study measures the market risks across industries in Vietnam before and during the COVID-19 period. Two important measures, the Value-at-Risk and the Conditional Value-at-Risk, are used for the 2012-2020 period. We then extend the analyses by estimating the market risks using the monthly VaR for the 2019-2020 period. Key findings from this study can be summarized as follows. First, market risks across the Vietnamese industries have changed significantly in response to the pandemic, both at the level and their rankings. Second, among the changes, the services industry appears to be hardest hit by the pandemic as expected, whereas the education sector has significantly improved its standing during these challenging times. Our analysis also confirms that complete lockdowns negatively affect the market risk of various Vietnamese industries. We note that the service industry is a critical contributor to the Vietnamese economy and that lockdown during the pandemic does matter to the market risk. Policy implications have emerged on these findings.
ABSTRACT
Condition:
Covid19;Vaccine ReactionIntervention:
Diagnostic Test: SARS-CoV-2 IgG II QuantPrimary outcome:
SARS-CoV-2 anti-RBD IgG concentrationCriteria:
Inclusion Criteria:
- People who lived in the two blocks (V and Y) of Ngo Gia Tu apartment, located in
District 10, Ho Chi Minh City, Vietnam, from July to September 2021
- 18 years of age and older
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- People who were diagnosed with primary or secondary immunodeficiencies induced by
diseases or medical treatments (immunosuppressants, chemotherapy, radiation therapy,
ect.)
ABSTRACT
Condition:
COVID-19 Respiratory Infection;Herbal MedicineIntervention:
Drug: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)Primary outcome:
Duration of symptoms of COVID-19;The severity of the COVID-19 total and individual symptoms;Rate of progression to disease severity;The time required to meet discharge standards;National Early Warning Score 2 (NEWS2)Criteria:
Inclusion Criteria:
- From full 18 to 64 years old;
- The patient was diagnosed with SARS-CoV-2 infection by RT-PCR confirmation (+) and CT
< 30.
- Patients classified as mild (acute upper respiratory tract infection): patients
infected with SARS-CoV-2 early in the first 5 days from the time of having one of the
non-specific clinical symptoms such as fever, cough dry, sore throat, stuffy nose,
fatigue, headache, muscle pain, decreased taste, decreased sense of smell. And there
are no signs of pneumonia or hypoxia, respiratory rate = 20 times/min, Saturation of
Peripheral Oxygen (SpO2) = 96% when breathing air.
- Patients classified as moderate (Pneumonia): patients infected with SARS-CoV-2 in the
first 10 days from the time of having one of the non-specific clinical symptoms,
showing signs of pneumonia (fever, cough, dyspnea, tachypnea >20 breaths/min) and no
signs of severe pneumonia, Saturation of Peripheral Oxygen (SpO2) = 93% when breathing
air.
- Inpatient treatment
- Subjects do not use any other medicines with herbal ingredients for underlying
conditions or any other purposes;
- Voluntary participation in the study by signing an informed consent
- Patients who have not been vaccinated or have just received 1 dose of COVID-19 vaccine
Exclusion Criteria:
- Severe or critical COVID-19 based on the COVID-19 severity scale of Vietnam Ministry
of Health;
- Chronic obstructive pulmonary disease, kidney failure requiring dialysis or creatinine
= 2.0mg/dl through medical history; parenteral or parenteral nutrition, uncontrolled
type 2 diabetes (HbA1c > 7%), uncontrolled hypertension (value > 160/100 mmHg),
uncontrolled coronary artery disease (new/currently established) requires medication
adjustment), heart failure, neurological disease (eg, acute stroke, polyneuritis
within 1 month) or mental illness, active tuberculosis, active autoimmune disease;
- Have a chronically weakened immune system (AIDS, cancer, undergoing
chemotherapy-radiotherapy in the past six months, immunosuppressive disease);
- Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant
or blood stem cell transplant);
- Allergic to products that contain ginseng;
- Pregnant or lactating women;
- Already participating in another clinical trial;
- The patient has received 2 doses of COVID-19 vaccine.
ABSTRACT
Condition:
Covid19Intervention:
Drug: Fluticasone PropionatePrimary outcome:
Incidence of adverse outcomesCriteria:
Inclusion Criteria:
1. Signing consent to participate in the study
2. Having COVID related-symptoms within 5 days prior to randomization
3. Confirmed diagnosis of COVID-19 by rapid antigen test or polymerase chain reaction
(PCR) test within 5 days prior to randomization
4. Over 50 years old OR 18-49 years old and have one or more of risk factors for severe
COVID-19
Exclusion Criteria:
1. Pregnant or breastfeeding woman
2. Allergy and/or contraindications to inhaled Fluticasone
3. Current or previous administration of inhaled corticosteroids within the 15 days prior
to randomization
4. Current or previous administration of high dose systemic corticosteroids (higher than
3.75 mg dexamethasone/day or equivalent doses of other corticosteroids) and/or
anticoagulants etc.. more than or equal to 2 days within 15 days prior randomization,
or taking any other antiviral drugs (such as remdesivir, favipiravir, etc..)
5. Indication for start of systemic corticosteroids or oxygen therapy or hospitalization
dut to COVID-19 within next 24 hours
6. Already participated in other interventional COVID studies
7. Any conditions for which the investigator believes that the patient should not
participate for the benefit of the patient or that would prevent, limit, or distort
the evaluation of the study procedure